Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $11.6 million.

  • Pulse Biosciences' Non-Current Assets fell 810.64% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.2 million, marking a year-over-year decrease of 713.34%. This contributed to the annual value of $13.0 million for FY2024, which is 589.47% down from last year.
  • As of Q3 2025, Pulse Biosciences' Non-Current Assets stood at $11.6 million, which was down 810.64% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Non-Current Assets registered a high of $18.6 million during Q1 2021, and its lowest value of $11.6 million during Q3 2025.
  • Over the past 5 years, Pulse Biosciences' median Non-Current Assets value was $14.3 million (recorded in 2023), while the average stood at $14.8 million.
  • The largest annual percentage gain for Pulse Biosciences' Non-Current Assets in the last 5 years was 2057.75% (2021), contrasted with its biggest fall of 2705.5% (2021).
  • Pulse Biosciences' Non-Current Assets (Quarter) stood at $13.8 million in 2021, then grew by 13.77% to $15.7 million in 2022, then decreased by 12.1% to $13.8 million in 2023, then dropped by 5.89% to $13.0 million in 2024, then dropped by 10.78% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $12.1 million for Q2 2025, and $12.5 million during Q1 2025.